Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Accumulated Depreciation (2017 - 2025)

Perspective Therapeutics' Accumulated Depreciation history spans 11 years, with the latest figure at $3.7 million for Q1 2025.

  • For Q1 2025, Accumulated Depreciation rose 263.55% year-over-year to $3.7 million; the TTM value through Mar 2025 reached $3.7 million, up 263.55%, while the annual FY2024 figure was $3.0 million, N/A changed from the prior year.
  • Accumulated Depreciation for Q1 2025 was $3.7 million at Perspective Therapeutics, up from $3.0 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $8.3 million in Q3 2023 and bottomed at $15000.0 in Q4 2022.
  • The 5-year median for Accumulated Depreciation is $3.3 million (2024), against an average of $4.2 million.
  • The largest annual shift saw Accumulated Depreciation tumbled 72.85% in 2024 before it skyrocketed 263.55% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $7.3 million in 2021, then plummeted by 99.79% to $15000.0 in 2022, then skyrocketed by 55240.0% to $8.3 million in 2023, then plummeted by 64.34% to $3.0 million in 2024, then grew by 24.66% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Accumulated Depreciation are $3.7 million (Q1 2025), $3.0 million (Q4 2024), and $2.3 million (Q3 2024).